The Creative Destruction Lab (CDL), an organization operating a collection of 13 global startup accelerators, has celebrated the completion of its Seattle-based program by ushering another group of early-stage companies into the market.
Established in 2021 at the University of Washington, the CDL’s Seattle accelerator stands out for its unique approach, as it does not acquire equity stakes in the companies it aids. The 9-month program receives support from its founding partners, such as the University itself and Microsoft.
An interesting aspect of the program is its strict adherence to objective-based milestones. Companies that fail to meet set benchmarks are subject to expulsion from the program.
More than 70 mentors, comprising founders, investors, and notable leaders from the Pacific Northwest, contribute to CDL-Seattle’s support network.
From nearly 300 applicants, the third cohort began with 40 startups, narrowing down to 17 by the time of graduation. The focus areas for Seattle’s CDL program are manufacturing and computational health.
Here is a list of the companies that have recently graduated:
Manufacturing
- Cibotica, a robotics firm specializing in food preparation
- DraftAid, creators of automated fabrication drawing software
- Enosemi, innovators in silicon photonics
- Integrate, a new player in collaboration and program management software
- Muse Engine, a manufacturer for small batch injection molding
- Nullspace, a developer of software for electromagnetic applications
- OpenSeam, a software solution for textile factories
- Phasio, a customer collaboration platform for manufacturers
- Plasmotion, experts in plasma electrolytic polishing
Computational Health
- 5 Prime Sciences, a drug development startup with a focus on human genetics
- Accipiter Biosciences, operating in stealth mode
- CalmWave, a software developer aiming to reduce ICU noise
- Cascade AI, an AI-based employee engagement software firm
- DocNexus, a search database platform for healthcare ecosystems
- Generable, builders of disease-specific models for drug development
- Sygomics, a personalized oncology startup predicting patient risk
- TMA Precision Health, a genomics-powered care navigation platform
